Care and research united in the fight against COVID-19
The unity of Lille’s institutions, which developed over time through the construction of the Experimental Public Institution (EPE), made it possible, among other things, to obtain funding from the board of directors of I-SITE Université Lille Nord Europe on 31 March. This will be invested into a 2 million-Euro emergency plan dedicated to research against COVID-19. This means that the task force constantly identifies and assesses research initiatives and their funding requirements.
To be eligible, projects submitted to the Task Force need to cover original research programmes that do not already exist in other contexts, and should lead to short or very short-term results, following one of the three directions below:
Presentation of current projects:
LIlle CORonavirus NEtwork (LICORNE) is a project designed for the creation of a clinical and biological data bank, with the building of a specific Covid-19 biobank. This biobank collects existing data to better understand the aggressive nature of the virus, find markers to predict whether the patients’ health condition will worsen and finally develop innovative diagnostic and monitoring tools.
CHU researchers and partners can get access to this cohort, upon request from a scientific council. It helps several projects, relying on the expertise of research units on the Lille site:
- Analysis of several hemostasis factors accounting for the risk of thrombosis (U1011)
- Analysis of inflammatory and autoimmune processes induced by Covid-19 (CIIL, Institut Pasteur de Lille and INFINITE)
- Study on the variability of the SARS-Cov-2 virus by genomic analysis and phenotypic correlation (CIIL, Institut Pasteur de Lille)
- Innovative approaches for rapid diagnostic methods (screening or serology) (Institute of Electronics, Microelectronics and Nanotechnology & PRISM laboratory)
The ultimate goal of the project is to systematically collect clinical and biological data from all patients admitted to the CHU for a possible Covid-19 table. In order to achieve this:
- All medical teams have worked on the development of a single-format collection of clinical data.
- Data will be collected both retrospectively and prospectively.
- A scientific committee has been constituted to handle future requests for use.
Publication rules have been defined.